Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 7:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 4,595 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Crossover Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study Between Tasimelteon Capsule Formulation and Liquid Suspension Formulation in Healthy Volunteers

NCT05572281
View directory record Official record
Conditions
Healthy
Interventions
Tasimelteon Oral Capsule, Tasimelteon Oral Suspension
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Oct 28, 2026, 7:37 PM EDT
Terminated Phase 2 Interventional

Tezosentan in Patients With Pulmonary Arterial Hypertension

NCT01094067
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
ACT-050089, Placebo
Drug · Other
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Oct 28, 2026, 7:37 PM EDT
Completed Not applicable Interventional

Use of Passive, Adaptive, and Active Prosthetic Knees in Persons With Unilateral, Transfemoral Amputation

NCT02219230
View directory record Official record
Conditions
Transfemoral Amputation
Interventions
Active knee (Ossur Power Knee II), Adaptive knee (Ossur Rheo), Passive knee (Various manufacturers)
Device
Lead sponsor
University of Washington
Other
Eligibility
45 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 28, 2015 · Synced Oct 28, 2026, 7:37 PM EDT
Terminated Phase 1 Interventional

Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors

NCT00701298
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
peginterferon alfa-2b, decitabine, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Feb 24, 2014 · Synced Oct 28, 2026, 7:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Color Correcting Lenses on Color Vision Deficiency

NCT05463016
View directory record Official record
Conditions
Color Blindness, Color Vision Defects, Color Blindness, Green, Color Blindness, Red
Interventions
Experimental Group 1: Color Correcting Lenses, Placebo Group 1: Placebo Lenses, Placebo Group 1 Crosses over to become Experimental Group 2: Color Correcting Lenses, Experimental Group 1 Crosses over to become Placebo Group 2: Placebo Lenses, Color Correcting Lenses in Subjects with Normal Color Vision
Device
Lead sponsor
University of the Incarnate Word
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 28, 2026, 7:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Bioavailability Crossover Study of Two Formulations of Lamotrigine Extended Release Tablets in Healthy Subjects

NCT02821338
View directory record Official record
Conditions
Healthy
Interventions
Lamotrigine Extended Release
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 1, 2020 · Synced Oct 28, 2026, 7:37 PM EDT
Completed Not applicable Interventional Results available

Clinical Trial of Multi-Periscopic Prism Glasses for Hemianopia

NCT04827147
View directory record Official record
Conditions
Homonymous Hemianopia
Interventions
Multi-Periscopic Prism (MPP) glasses, Fresnel Peripheral Prism (FPP) glasses
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
7 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
8
States / cities
Birmingham, Alabama • Denver, Colorado • Palm Springs, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 28, 2026, 7:37 PM EDT
Completed Phase 1 Interventional

A Study of RO5045337 in Patients With Solid Tumors

NCT01164033
View directory record Official record
Conditions
Neoplasms
Interventions
RO5045337
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
5
States / cities
Scottsdale, Arizona • Kansas City, Kansas • Kensignton, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 28, 2026, 7:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single-Center, Open-Label, Randomized, 3-Treatment Crossover Bioavailability Study of Single Oral Doses of E5501 Old Tablet Formulation Under Fasted Conditions and a New Tablet Formulation Under Fed and Fasted Conditions in Healthy Subjects

NCT01260155
View directory record Official record
Conditions
Healthy Subjects
Interventions
E5501
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Oct 28, 2026, 7:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study To Evaluate The Effect Of Single Intravenous Doses Of Tigecycline On QTc Intervals In Healthy Subjects

NCT01287793
View directory record Official record
Conditions
Healthy
Interventions
tigecycline, moxifloxacin, 100 mL 0.9% Sodium Chloride intravenous, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 24, 2011 · Synced Oct 28, 2026, 7:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Levels of CAZ-AVI and Metronidazole in the Blood When Given Together and Separately

NCT01534247
View directory record Official record
Conditions
Healthy
Interventions
CAZ-AVI, metronidazole, CAZ-AVI + metronidazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Oct 28, 2026, 7:37 PM EDT
Completed Not applicable Interventional Results available

Guidance of Ultrasound in Intensive Care to Direct Euvolemia

NCT03938038
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Serial ultrasound assessments for GDT, Usual care
Diagnostic Test
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
16 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2024 · Synced Oct 28, 2026, 7:37 PM EDT
Completed Not applicable Interventional Results available

Cooled Radiofrequency vs. Hyaluronic Acid to Manage Knee Pain

NCT03381248
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
Cooled Radiofrequency, Hyaluronic Acid Injection, Crossover from Hyaluronic Acid Injection to Cooled Radiofrequency
Device · Other
Lead sponsor
Avanos Medical
Other
Eligibility
21 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
10
States / cities
Coeur d'Alene, Idaho • New Orleans, Louisiana • Rochester, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 28, 2026, 7:37 PM EDT
Completed Phase 2 Interventional Results available

Effect of a Wide Spectrum Nutritional Supplement on Mitochondrial Function in Children With Autism Spectrum Disorder

NCT03835117
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Wide-spectrum nutritional supplement, Placebo
Drug · Other
Lead sponsor
Rossignol Medical Center
Other
Eligibility
2 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 28, 2026, 7:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

PK Study of PT003 and PT001 in Japanese Healthy Subjects

NCT02196714
View directory record Official record
Conditions
COPD
Interventions
Glycopyrronium and Formoterol Fumarate (GFF) Dose 1, Glycopyrronium and Formoterol Fumarate (GFF) Dose 2, Glycopyrronium (GP) Dose 1, Glycopyrronium (GP) Dose 2
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 28, 2026, 7:37 PM EDT
Active, not recruiting Not applicable Interventional

Evaluating SUI-100™, A Non-Invasive Device for the Treatment of Stress Urinary Incontinence

NCT06862648
View directory record Official record
Conditions
Stress Urinary Incontinence (SUI)
Interventions
Acoustic Stimulation Therapy Device, Sham Acoustic Stimulation Therapy Device
Device
Lead sponsor
Acoustic Wave Cell Therapy, Inc.
Industry
Eligibility
22 Years to 77 Years · Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Phoenix, Arizona • Lakeland, Florida • Boise, Idaho + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 28, 2026, 7:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Food Effect and the Relative Bioavailability of the Cabotegravir (CAB) Pediatric Dispersible Tablet (DT) Formulation

NCT05776108
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir IR Formulation (reference), Cabotegravir DT Formulation (test 1), Cabotegravir DT Formulation (test 2)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 28, 2026, 7:37 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users

NCT06097676
View directory record Official record
Conditions
Abuse Potential
Interventions
Placebo, Alprazolam 2 mg, Gabapentin Enacarbil Immediate Release (GE-IR) 200 mg, Gabapentin Enacarbil Immediate Release (GE-IR) 450 mg, Gabapentin Enacarbil Immediate Release (GE-IR) 700 mg
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 28, 2026, 7:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study to Assess an LC350189 Tablet Compared to an LC350189 Capsule in Healthy Adults

NCT04886050
View directory record Official record
Conditions
Gout, Hyperuricemia
Interventions
LC350189 Tablet, LC350189 Capsule
Drug
Lead sponsor
LG Chem
Industry
Eligibility
18 Years to 50 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jan 6, 2022 · Synced Oct 28, 2026, 7:37 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Treximet Early Intervention Adolescent Migraine

NCT01016678
View directory record Official record
Conditions
Migraine
Interventions
Treximet, Placebo
Drug
Lead sponsor
Premiere Research Institute
Other
Eligibility
12 Years to 17 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
4
States / cities
West Palm Beach, Florida • Cincinnati, Ohio • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Oct 28, 2026, 7:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Hemodynamic Response to to a Sublingual Dose of Glyceryl Trinitrate in Subjects Receiving TA-1790, Sildenafil Citrate, and Placebo

NCT01616485
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
TA-1790, Sildenafil citrate, Placebo, Nitrostat
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
30 Years to 60 Years · Male only
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Oct 28, 2026, 7:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Healthy Volunteer Study to Establish the Bioequivalence of BG00012 Supplied by 2 Different Commercial Manufacturers

NCT02171208
View directory record Official record
Conditions
Healthy
Interventions
dimethyl fumarate - Reference form, dimethyl fumarate - Test form
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Daytona Beach, Florida • Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 9, 2015 · Synced Oct 28, 2026, 7:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Profile of MT101-5 in Healthy Volunteers

NCT05844787
View directory record Official record
Conditions
Parkinson's Disease
Interventions
MT101-5
Drug
Lead sponsor
Mthera Pharma Co., Ltd.
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 28, 2026, 7:37 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Keppra and Clonidine in the Treatment of Tics

NCT00370838
View directory record Official record
Conditions
Tic Disorders, Tourette Syndrome
Interventions
Levetiracetam, Clonidine
Drug
Lead sponsor
Harvey S. Singer
Other
Eligibility
7 Years to 19 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 7, 2011 · Synced Oct 28, 2026, 7:37 PM EDT